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DiagnosisAbstract Background: Serum alpha-fetoprotein (AFP) has insufﬁcient sensitivity and speciﬁcity
for detection of hepatocellular carcinoma (HCC). Recently, glypican-3 (GLP-3) was suggested as
a new biomarker for the detection HCC.
Objectives: To determine the role of serum GLP-3 levels in the early diagnosis and differentiation
of small (3 cm or less in diameter) HCC from liver cirrhosis. Also, to correlate GLP-3 levels to cli-
nico-laboratory data.
Methods: The study included sixty patients; 30 of them with hepatitis C virus (HCV) cirrhosis, and
30 patients with proved HCC. In addition, 20 healthy subjects were included as a control group.
Clinical and radiological features (abdominal ultrasonography and/or abdominal triphasic com-
puted tomography) were recorded. Liver function tests, complete blood cell count, and serum
AFP were measured. Serum GLP-3 values were determined by an ELISA technique.
Results: Serum levels of GLP-3 were signiﬁcantly elevated in patients with HCC compared with
HCV cirrhosis group (p< 0.001). Also, these levels were signiﬁcantly elevated in these two patients’
groups versus controls (p< 0.001). Also, serum GLP-3 levels with cut-off value ofP240 ug/L, had
a higher sensitivity (100%) and same speciﬁcity (93.3%), than AFP with cut-off value ofP200 ng/
ml, for detection of HCC. Moreover, GLP-3 levels showed a higher sensitivity than AFP (50%
vs.41.7%), for detection of small HCC. The combined use of both markers (i.e. when either one
of the two markers positive) improved the speciﬁcity to 88.9%. Regarding unicentric HCC,
222 E.A.E. Badr et al.GLP-3 at cut-off value of 6580 ug/L had better speciﬁcity than AFP at cut-off value of 6765 ng/ml
(57.1% vs. 42.9%). The combined use of both markers improved the sensitivity and speciﬁcity to
82.6% and 71.4%, respectively.
Conclusion: Serum GLP-3 levels are higher in HCC versus HCV cirrhosis, which can differentiate
HCC from liver cirrhosis. Also, serum GLP-3 is highly sensitive and speciﬁc for detecting HCC.
Moreover, GLP-3 is more sensitive than AFP for the detection of small HCC. Furthermore, a com-
bination of both serum markers yielded an improved speciﬁcity and both sensitivity and speciﬁcity
for the diagnosis of small and unicentric HCC, respectively.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Hepatocellular carcinoma (HCC) represents the ﬁfth most
common cancer worldwide and the third most common cause
of cancer death.1 It constitutes about 70% of all liver tumors
among Egyptians.2 The HCV infection is the most common
risk factor of HCC in Egypt which leads to cirrhosis and severe
liver damage.3,4 The HCC is frequently diagnosed at late
stages.5,6 HCC is usually asymptomatic in the early stages,
and most patients present with incurable disease at the time
of detection, so early diagnosis of HCC is critical for a good
prognosis.7
Although ultrasonography (US) has been widely used in
clinical screening of HCC,8 it is very operator dependent and
less reliable in obese and cirrhotic subjects.9 Alpha-fetoprotein
(AFP) is the only serological marker currently widely used for
the diagnosis of HCC.10 AFP is not secreted in all cases of
HCC and may be normal in as many as 40% of patients with
early HCC. On the other hand, the AFP level can reach high
levels (2500 lg/L) in around one fourth of patients with
chronic hepatitis, and liver cirrhosis.11 In contrast, GLP-3 is
a 60 KDa cell surface-linked heparin sulfate proteoglycan,
which is not expressed in adult liver, was ﬁrst introduced as
a possible tumor marker of HCC by observing signiﬁcantly
high levels of this protein in the serum of HCC patients.12,13
As patients with cirrhosis may develop HCC only after
many years, emphasis has been placed on the early detection
of HCC when it is small, asymptomatic and potentially cur-
able.12 So, this study aimed to estimate serum GLP-3 levels
in patients with cirrhosis and HCC, versus healthy controls.
Also, to deﬁne the role of serum GLP-3 levels in the early diag-
nosis and differentiation of small (diameter of 3 cm or less)
HCC from liver cirrhosis, and to correlate these levels with cli-
nico-laboratory data.2. Patient and methods
2.1. Patients’ selection
During the period from June 2012 to June 2013, we selected
sixty patients from the tropical, and internal medicine depart-
ments, as well as the oncology center, of the university hospital
and faculty of medicine, Menouﬁya University, Egypt.
Thirty of these patients were diagnosed as HCC. All HCC
patients were newly diagnosed cases and did not receive prior
chemotherapy. Tumor biopsy was carried out in twelve
patients (40%) and showed that eight of them had poorlydifferentiated HCC, and the other four had well differentiated
HCC. Tumor biopsy was not done in the remaining eighteen
HCC patients, because either the tumor site was difﬁcult for
the biopsy to be taken and/or there was contraindication to
biopsy. HCC was diagnosed according to history, clinical
examination, classic radiological investigations [abdominal
ultrasonography (US) and/or triphasic computed tomogra-
phy], serum AFP levels above 200 ng/ml, and/or histopatholo-
gical examination of tissue biopsy when available.14
The remaining thirty patients have HCV liver cirrhosis.
Liver cirrhosis was diagnosed by history, clinical features of
cirrhosis, abdominal US features, laboratory investigations
and/or liver biopsy.
Twenty healthy subjects matched for gender and age were
included and served as controls. All controls had normal liver
function tests, and were seronegative for hepatitis B markers
(HBs Ag, HBeAg and HBc-Ab) and HCV antibodies. The
study was approved by our local ethics committee of the uni-
versity hospitals and informed oral consent was obtained from
all participants.
2.2. Laboratory assays
10 ml of fasting venous blood for at least 10 h was withdrawn
from all subjects. Plasma was obtained from 1.8 ml of whole
blood, was added to 0.2 ml sodium citrate, centrifuged at
4000 rpm for 5 min, and then plasma was used for measuring
prothrombin concentration by using Fibrintimer II instrument
of Behring, Germany Using Sysmex K-21, Japan. Two ml of
whole blood was added to EDETA containing tubes with good
mixing then automated homogram was done for all samples,
including hemoglobin estimation (HB), red cell count (RBCs),
total leukocytic count (TLC) and platelet count. These param-
eters were determined by colter counter model Beckman750,
Int, L.S.A. Six ml of venous blood was transferred slowly into
a plain tube, allowed to clot, and then centrifuged for 10 min.
The clear supernatant was separated in several aliquots, kept
frozen at 20 C, till analysis. The following investigations
were carried out by auto analyzer (SYNCHRON CX5 from
Beckman): liver function tests including: alanine transaminase
(ALT), aspartate transaminase (AST), serum albumin and
total bilirubin. Kidney function tests including; serum urea
and creatinine were done. Hepatitis markers (HBsAg, and
HCV antibodies) were done by the ELISA technique15,16 while
anti-HBc antibodies were detected by Electro-Chemi-Lumines-
cence Immunoassay (ECLIA).17
Serum AFP levels were measured by ELISA (MONBIND,
Inc. Costa Mesa, CA92627 USA).
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polymerase chain reaction (RT-PCR) using a commercial kit
(Roche Diagnostic, Branchburg, NJ) according to the manu-
facturer’s instructions.
Serum GLP-3 was determined by ELISA Kit provided by
Uscn, (Inc-USA). This assay employs the quantitative sand-
wich enzyme immunoassay technique.18
2.3. Statistical analysis
All statistical analyses were performed using the Statistical
Package for Social Science (SPSS) software version 10. Results
are presented as mean ± standard deviation (SD) unless
otherwise stated. For comparison of two means, the non-para-
metric Mann–Whitney test was used. The ANOVA test was
used to compare among HCV-cirrhosis with HCC and con-
trols. Fisher exact analysis was also applied to compare pro-
portions between groups. Spearman correlation analysis was
used to study correlations between different parameters. A
P-value of 60.05 was considered statistically signiﬁcant. Sensi-
tivity, speciﬁcity, positive predictive value (PPV), negative pre-
dictive value (NPV), and diagnostic accuracy, were calculated
from 2 · 2 tables. Cut-off point values were calculated from
ROC curves.3. Results
Thirty patients were diagnosed as HCC. They were 25 males
and 5 females, with their mean age ± SD of 56.97 ± 10.94
years. Another thirty patients had HCV liver cirrhosis. They
were 23 males and 7 females, their mean age ± SD of
53.26 ± 5.34 years. In addition, twenty healthy subjects were
included and served as controls (16 males; 4 females; age
57.1 ± 6.9 years). Age and gender were not signiﬁcantly differ-
ent among the three studied groups (p> 0.05). Regarding
Child Pugh classiﬁcation, 7 (23.3%), 14(46.7%), and 9
(30%), patients with cirrhosis were in class A, B, and C,
respectively. In contrast, 11 (36.7%), 10 (33.3%), and 9
(30%), patients with HCC were in class A, B, and C, respec-
tively. There was no signiﬁcant difference between the twoTable 1 Laboratory data of the studied patients.
Cirrhosis N= 30
X± SD
Hemoglobin (g/dl) 10.46 ± 1.61
Leukocyte count (·103/L) 7.13 ± 5.72
Platelets (·103/L) 105.23 ± 68.42
Urea mg/dl 43.87 ± 18.74
Creatinine (mg/dl) 1.37 ± 0.49
AST (IU/ml) 42.23 ± 13.78
ALT (IU/ml) 33.57 ± 18.44
Total bilirubin (mg/dl) 2.62 ± 1.54
Direct bilirubin (mg/dl) 1.11 ± 0.89
Serum albumin (mg/dl) 2.36 ± 0.47
Prothrombin time (%) 55.30 ± 13.60
Serum AFP (ng/ml) 80.04 ± 100.92
Serum glypican-3 (ug/L) 98.23 ± 73.54
HCC=Hepatocellular carcinoma AFP = Alpha-fetoprotein.
AST = Aspartate transaminase ALT= Alanine transaminase.
* Signiﬁcant.groups (p= 0.46). Considering tumor size, 12 (40%) and 18
(60%) patients had small and large size HCC, respectively.
Out of thirty HCC patients, twenty-three (76.7%) had unicen-
tric tumor, and the rest (23.3%) had multicentric tumor.
Twenty-three patients (76.6%) with HCC had the tumor
located in the right lobe of the liver, and the rest (23.3%) in
the left lobe.
Table 1, shows the laboratory data of the studied patients.
There was a signiﬁcant increase in serum creatinine, total and
direct bilirubin, AFP and GLP-3 in HCC versus HCV cirrhosis
group (p< 0.05). Also, serum AFP, and GLP-3 levels were
signiﬁcantly higher in these two groups, compared with the
control group, with higher levels in HCC versus HCV cirrhosis
group (p< 0.05). In contrast, platelet count, and serum albu-
min level, were signiﬁcantly decreased in HCC versus HCV cir-
rhosis group (p< 0.05).
Correlation between serum GLP-3 levels and other labora-
tory parameters in HCC patients, is shown in Table 2. A sig-
niﬁcant positive correlation was found between serum GLP-3
level and blood urea, serum creatinine, AST, ALT, total and
direct bilirubin, and AFP (p< 0.05). In contrast, a signiﬁcant
negative correlation was found between serum GLP-3 and
hemoglobin concentration, platelet count, and prothrombin
time (p< 0.05).
Also, on comparing serum GLP-3 levels with tumor charac-
teristics of HCC patients, a signiﬁcant difference was detected
between serum GLP-3 level and some tumor characteristics,
namely, unicentric tumor, portal vein thrombosis (tumor
embolization), and tumor location in right hepatic lobe
(p= 0.002, >0.001, and >0.001, respectively). However,
there was no signiﬁcant difference with Child Pugh class
(p= 0.14).
Regarding HCC diagnosis, (Table 3), AFP at a cut-off
value P200 ng/ml had a sensitivity, speciﬁcity, PPV, and
NPV of 83.3%, 93.3%, 92.6%, and 84.8% for HCC diagnosis,
respectively. In contrast, GLP-3, at a cut-off valueP240 ug/L
had a sensitivity, speciﬁcity, PPV, and NPV of 100%, 93.3%,
93.8%, and 100% for HCC diagnosis, respectively. Combined
use of both markers (i.e. when either one of the two markers
positive), at same cut-off values, increased sensitivity, speciﬁc-
ity, PPV, and NPV to 100%, for HCC diagnosis.HCC N= 30 Mann–Whitney Test
X ± SD
9.76 ± 1.57 P> 0.05
7.03 ± 5.63 P> 0.05
72.57 ± 24.11 P< 0.01*
53.83 ± 26.73 P> 0.05
2.08 ± 1.01 P< 0.01*
58.13 ± 57.48 P> 0.05
39.57 ± 20.33 P> 0.05
4.80 ± 2.69 P< 0.01*
1.85 ± 1.31 P< 0.05*
2.82 ± 0.76 P< 0.01*
54.63 ± 14.07 P> 0.05
703.43 ± 744.69 P< 0.01*
551.47 ± 185.25 P< 0.01*
Table 2 Correlation between serum glypican-3 levels and
other laboratory parameters in HCC group.
Serum glypican-3
Spearman correlation analysis P value
Hemoglobin 0.45 <0.001*
Leukocyte count 0.04 0.75
Platelets 0.52 <0.001*
Urea +0.37 0.001*
Creatinine +0.53 <0.001*
AST +0.27 0.01*
ALT +0.24 0.03*
Total bilirubin +0.55 <0.001*
Direct bilirubin +0.45 <0.001*
Serum albumin 0.21 0.06
Prothrombin time 0.41 <0.001*
Serum AFP +0.61 <0.001*
HCC=Hepatocellular carcinoma.
AST = Aspartate transaminase.
ALT= Alanine transaminase.
AFP = Alpha-fetoprorein.
* Signiﬁcant.
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large size of more than 3 cm in diameter), (Table 4), AFP at
a cut-off value 6300 ng/ml had a sensitivity, speciﬁcity, PPV,
and NPV of 41.7%, 83.3%, 62.5%, and 68.2%, for diagnosis
of small HCC, respectively. In contrast, GLP-3, at a cut-off
value 6560 ug/L had sensitivity, speciﬁcity, PPV, NPV of
50%, 50%, 40%, and 60% for diagnosis of small HCC, respec-
tively. Combined use of both markers (AFP or GLP-3), at
same cut-off values, increased speciﬁcity, PPV, and NPV to
88.9%, 75%, and 72.7%, respectively; whereas, sensitivity
was not changed for diagnosis of small HCC.
In respect to unicentric and multicentric HCC, (Table 5),
AFP at a cut-off value 6765 ng/ml had a sensitivity, speciﬁc-
ity, PPV, and NPV of 73.9%, 42.9%, 81%, and 33.3% for
diagnosis of unicentric HCC, respectively. In contrast, GLP-
3, at a cut-off value 6580 ug/L had sensitivity, speciﬁcity,
PPV, and NPV of 65.2%, 57.1%, 83.3%, and 33.3% for diag-
nosis of unicentric HCC, respectively. Combined use of both
markers (AFP or GLP-3), at same cut-off values, increased
sensitivity, speciﬁcity, PPV, and NPV to 82.6%, 71.4%,
90.5%, and 55.6%, respectively, for diagnosis of unicentric
HCC.Table 3 Predictive power of serum AFP, GLP-3, and combined (A
AFP: cut oﬀ
pointP 200 ng/ml
GLP-
point
HCC+ ve
(n= 30)
HCC –ve
(n= 30)
HCC
(n=
Tumor marker (+ve) 25 2 30
Tumor marker (ve) 5 28 0
Sensitivity 83.3% 100%
Speciﬁcity 93.3% 93.3%
PPV 92.6% 93.8%
NPV 84.8% 100%
Accuracy of the test 88.3% 96.7%
AFP= Alpha-fetoprotein; GLP-3 = Glypican-3; HCC=Hepatocellul
predictive value.4. Discussion
Hepatocellular carcinoma most frequently develops in patients
with cirrhosis related to chronic viral hepatitis.19 The use of
biomarkers in predicting disease holds considerable promise
and has played an important role in early diagnosis.20 In
HCC, GLP-3 fosters HCC growth by altering Wnt signaling,21
modulating growth factors such as insulin-like growth factor-2
(IGF-2), bone morphogenetic protein-9 (BMP-9), and ﬁbro-
blast growth factor-2 (FGF-2) and possibly by playing a role
in M2 macrophage recruitment.22 GLP3 may be cleaved from
the surface of expressing hepatocytes, thereby entering the
circulation.23
In the present study, we found that serum levels of GLP-3
were signiﬁcantly higher in patients with HCC compared with
HCV cirrhosis group. Also, these levels were signiﬁcantly
higher in these two patients’ groups versus controls. These
results are in agreement with many studies.5,24–26
Several studies have demonstrated the efﬁcacy of GLP-3 as
a diagnostic tool in HCC. It was reported that the sensitivity
and speciﬁcity ranged from 47–93.3%, and 41.8–100%, respec-
tively.7,12,24,27,28 This wide range of difference may be due to
different patients’ characteristics, the presence of HCV as an
etiological factor for HCC,24 or using different cut-off values
for GLP-3. Our results are similar to the literature, with
100% sensitivity and speciﬁcity, for HCC diagnosis.
Consistent with our and these previous studies, tumors aris-
ing in cirrhotic liver are more likely to express GLP-3.5,29 Also,
in line with our work, recently the American Association for
the Study of Liver Disease has stated in management of
HCC that ‘Expert pathology diagnosis is reinforced by stain-
ing for GLP-3, heat shock protein 70 and glutamine synthe-
tase, because positivity for two of these three stains conﬁrms
HCC’.30 Likewise, the Clinical Practice Guidelines of the
European Association for the Study of the Liver recommend
the use of these three markers to conﬁrm HCC diagnosis.31
In contrast, Yasuda et al.32 and Ozkan et al.33 reported that
there was no increase in serum GLP-3 level in patients with
HCC, and serum GLP-3 level was not a useful diagnostic mar-
ker for HCC. This may be due to the measuring procedure
used in these studies, as suggested by the former.
Regarding AFP, it was reported that the sensitivity and
speciﬁcity ranges from 36.3–83.3%, and 60–100%, respec-
tively.24,27,28,33 Our results were in accordance with theseFP or GLP-3) in the diagnosis of HCC.
3: cut oﬀ
P 240 ug/L
Combined GLP-3: cut oﬀ
pointP 200 ug/L OR AFP:
cut oﬀ pointP 240 ng/ml
+ ve
30)
HCC ve
(n= 30)
HCC+ ve
(n= 30)
HCC ve
(n= 30)
2 30 0
28 0 30
100%
100%
100%
100%
100%
ar carcinoma; PPV = Positive predictive value; NPV=Negative
Table 4 Predictive power of serum AFP, GLP-3, and combined (AFP or GLP-3) in the diagnosis of small HCC (diameter 6 3 cm).
AFP: cut oﬀ point
6 300 ng/ml
GLP-3: cut oﬀ point
6 560 ug/L
Combined GLP-3: cut oﬀ point
6 560 ug/L OR AFP:
cut oﬀ point 6 300 ng/ml
HCC 6 3 cm +ve
(n= 12)
HCC 6 3 cm –ve
(n= 18)
HCC 6 3 cm + ve
(n= 12)
HCC 6 3 cm –ve
(n= 18)
HCC 6 3 cm + ve
(n= 12)
HCC 6 3 cm –ve
(n= 18)
Tumor marker (+ve) 5 3 6 9 6 2
Tumor marker (ve) 7 15 6 9 6 16
Sensitivity 41.7% 50.0% 50.0%
Speciﬁcity 83.3% 50.0% 88.9%
PPV 62.5% 40.0% 75.0%
NPV 68.2% 60.0% 72.7%
Accuracy of the test 66.7% 50.0% 73.3%
AFP= Alpha-fetoprotein; GLP-3 = Glypican-3; HCC=Hepatocellular carcinoma; PPV= Positive predictive value; NPV=Negative
predictive value.
Table 5 Predictive power of serum AFP, GLP-3, and combined (AFP or GLP-3) in the diagnosis of unicentric HCC.
AFP: cut oﬀ point 6 765 ng/ml GLP-3: cut oﬀ point 6 580 ug/L Combined GLP-3: cut oﬀ point
6 580 ug/L OR AFP: cut oﬀ point 6 765 ng/ml
HCC
(unicentric)
+ve (n= 23)
HCC
(unicentric)
–ve (n= 7)
HCC
(unicentric)
+ve (n= 23)
HCC
(unicentric) –ve
(n= 7)
HCC
(unicentric)
+ve (n= 23)
HCC
(unicentric)
–ve (n= 7)
Tumor marker(+ve) 17 4 15 3 19 2
Tumor marker (ve) 6 3 8 4 4 5
Sensitivity 73.9% 65.2% 82.6%
Speciﬁcity 42.9% 57.1% 71.4%
PPV 81.0% 83.3% 90.5%
NPV 33.3% 33.3% 55.6%
Accuracy of the test 66.7% 63.3% 80.0%
AFP= Alpha-fetoprotein; GLP-3 = Glypican-3; HCC=Hepatocellular carcinoma; PPV= Positive predictive value; NPV=Negative
predictive value.
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tively). In agreement with previous studies, our data also
showed that the simultaneous measurement of AFP and
GLP-3 will improve the speciﬁcity for HCC diagnosis.24,25,34
We found that serum GLP-3 levels were not correlated with
tumor size and Child-Pugh class. However, for HCC with
small tumor size (diameter equal or smaller than 3 cm), we
found that GLP-3 at cut-off value of 6560 ug/l had superior
sensitivity than AFP at cut-off values of 6300 ng/ml (50%
and 41.7%, respectively). Also, the combined use of both
markers improved the speciﬁcity to 88.9%. These ﬁndings were
in agreement with previous studies.18,24,25,34 In respect to the
unicentric HCC, we found that the combined use of GLP-3
at cut-off value of 6580 ug/L, and AFP at cut-off values of
6765 ng/ml, improved both sensitivity and speciﬁcity for diag-
nosis. This is in agreement with previous study.24
5. Conclusion
Serum GLP-3 is highly sensitive and speciﬁc for detecting
HCC, and differentiating HCC from liver cirrhosis. Also,
GLP-3 is more sensitive than AFP for the detection of smaller
HCC, with diameter of 3 cm or less. Moreover, a combination
of both markers yielded an improved speciﬁcity and bothsensitivity and speciﬁcity for the diagnosis of small and unicen-
tric HCC, respectively.6. Limitations of the study
This work included a relatively small number of patients,
which may affect the ﬁnal conclusions. In addition, the experi-
ence with GLP-3 is still limited and its expression in adenocar-
cinomas of various sites and other tumors that can mimic
HCC such as renal cell carcinoma have not been widely
studied. Also, some studies have reported negative results in
cholangiocarcinomas and majority of metastatic adenocarci-
nomas,26,35 but GLP-3 expression has been described in mela-
nomas, ovarian carcinoma and rarely in metastatic colonic
adenocarcinoma.36,37 Moreover, it was reported that, 14% of
the metastases from gastrointestinal, and pancreatic tumors,
are positive for GLP-3, suggesting that this marker might be
not very speciﬁc for distinguishing HCC from extra-hepatic
metastases.38
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